Stockscreener 앱 받기
3.62
4.23%
-0.16
시간 외 거래:
3.69
0.07
+1.93%
전일 마감가:
$3.78
열려 있는:
$3.78
하루 거래량:
602.36K
Relative Volume:
0.91
시가총액:
$329.37M
수익:
$114.70K
순이익/손실:
$-26.49M
주가수익비율:
-1.4677
EPS:
-2.4665
순현금흐름:
$-53.17M
1주 성능:
-3.98%
1개월 성능:
+3.13%
6개월 성능:
-3.21%
1년 성능:
+64.96%
1일 변동 폭
$3.61
$3.78
1주일 범위
$3.61
$3.88
52주 변동 폭
$1.85
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.62 | 336.65M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-19 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
SAB Biotherapeutics Reports $22.5M Net Loss in Q2 2026 Amid Balance Sheet Growth - Kalkine Media
SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
SAB Biotherapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
SABS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Development CostsEarnings Miss Streak - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
SAB Biotherapeutics Warrant (SABSW) Jumps 40.85% to $0.02 Amid Renewed Speculative InterestHigh Reward Trades - vinanet.vn
SABSW Edges Higher in Thin Trading: Warrant Holds at $0.01MFI Overbought - vinanet.vn
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS - TradingView
SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.900|Chg%:+0.050 - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
SABSW Plunges 43% to Penny Level: SAB Biotherapeutics Warrant Hits New LowHull Moving Average - dars.gov.et
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
SAB Biotherapeutics Warrants (SABSW) Surge 34%: Low-Priced Derivative Sees Sharp MoveMESA MA - vinanet.vn
SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.00%
3.22%
자본화:
|
볼륨(24시간):